Efficacy and safety of adapalene gel as a reactive treatment for cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck: A historical cohort comparison study
Restricted accessResearch articleFirst published online March, 2024
Efficacy and safety of adapalene gel as a reactive treatment for cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck: A historical cohort comparison study
Despite the common occurrence of cetuximab (Cmab)-induced skin toxicity, management strategies are not well established. The traditional mainstay method consists of topical steroids, which, if used excessively, may give rise to other concerns. Alternatively, adapalene can activate epidermal growth factor receptor pathways to potentially alleviate these toxicities.
Methods
We prospectively studied 31 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who were eligible to use adapalene gel as a reactive treatment for topical steroid-refractory skin toxicity. For comparison, we retrospectively reviewed 99 patients with R/M SCCHN (historical control cohort) whose skin toxicity was mainly treated with topical steroids. We compared the frequency and severity of Cmab-induced skin toxicity, Cmab therapy status (e.g., dose modification), side effects caused by topical steroids and adapalene gel itself, and other medical interventions.
Results
Adapalene gel was used by eight patients (25.8%) in the prospective cohort. Patients in the historical control cohort more frequently required escalation of topical steroid potency (34.3% vs. 12.9%, p = 0.022). Although there was no statistically significant difference in the frequency of grade ≥3 facial skin rash and paronychia between the two cohorts, the prospective cohort showed a significantly shorter time to complete recovery from grade 2/3 paronychia (16 vs. 47 days, p = 0.017). Further, while no skin infections were observed in the prospective cohort, 13 patients in the historical control cohort developed skin infections, especially periungual infection (0% vs. 13.1%, p = 0.024). In addition, no patients in the prospective cohort received a dose reduction of Cmab due to skin toxicities, compared to 20 patients in the historical control cohort (0% vs. 20.2%, p = 0.003). No apparent adapalene gel-related side effects were observed.
Conclusions
Adapalene gel may be an effective management option for topical steroid-refractory Cmab-induced skin toxicities and could improve compliance with Cmab therapy.
GoldsteinNIPrewettMZuklysK, et al.Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res1995; 1: 1311–1318.
2.
LiSSchmitzKRJeffreyPD, et al.Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell2005; 7: 301–311.
3.
SatoJDKawamotoTLeAD, et al.Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med1983; 1: 511–529.
4.
KangXPatelDNgS, et al.High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab. J Clin Oncol2007; 25(Suppl): 128 s. abstract.
5.
KimuraHSakaiKAraoT, et al.Antibodydependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci2007; 98: 1275–1280.
6.
ZhangWGordonMSchultheisAM, et al.FCGR2A And FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol2007; 25: 3712–3718.
7.
Rubin GrandisJMelhemMFGoodingWE, et al.Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst1998; 90: 824–832.
8.
ChungCHElyKMcGavranL, et al.Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol2006; 24: 4170–4176.
9.
TemamSKawaguchiHEl-NaggarAK, et al.Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol2007; 25: 2164–2170.
10.
VermorkenJBMesiaRRiveraF, et al.Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med2008; 359: 1116–1127.
11.
BonnerJAHarariPMGiraltJ, et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med2006; 354: 567–578.
12.
SalehKDasteAMartinN, et al.Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer2019; 121: 123–129.
13.
Cabezas-CamareroSCabrera-MartinMNMerino-MenendezS, et al.Safety and efficacy of cetuximab-based salvage chemotherapy after checkpoint inhibitors in head and neck cancer. Oncologist2021; 26: e1018–e1035.
14.
RischinDHarringtonKJGreilR, et al.Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. J Clin Oncol2020; 38: 6530–6530.
15.
NaughtonMJSchragDVenookAP, et al.Quality of life (QOL) and toxicity among patients in CALGB 80405. J Clin Oncol2013; 31(Suppl): Abstract 3611.
16.
HaleyACCalahanCGandhiM, et al.Skin care management in cancer patients: an evaluation of quality of life and tolerability. Support Care Cancer2011; 19: 545–554.
17.
WagnerLILacoutureME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology2007; 21: 34–36.
18.
LacoutureME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer2006; 6: 803–812.
19.
BonnerJAHarariPMGiraltJ, et al.Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5 year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol2010; 11: 21–28.
20.
SaltzLBKiesMSAbbruzzeseJL, et al.The presence and intensity of the cetuximab-induced acne like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol2003; 21(Suppl): Abstract817.
21.
OrdituraMDe VitaFGaliziaG, et al.Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep2009; 21: 1023–1028.
22.
GatzemeierUvon PawelJVynnychenkoI, et al.First cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol2011; 12: 30–37.
23.
Van CutsemEKohneCHHitreE, et al.Cetixumab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009; 360: 1408–1417.
24.
CunninghamDHumbletYSienaS, et al.Cetuximab monotherapy and cetuximab plus irinotecan in inrinotecan-refractory metastatic colorectal cancer. N Engl J Med2004; 351: 337–345.
25.
LenzHJVan CutsemEKhambata-FordS, et al.Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinoteacn, oxaliplatin, and fluoropyrimidines. J Clin Oncol2006; 24: 4914–4921.
26.
JonkerDJO’CallaghanCJKarapetisCS, et al.Cetuximab for the treatment of colorectal cancer. N Engl J Med2007; 357: 2040–2048.
27.
JimenezBTrigoJMPajaresBI, et al.Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. Oral Oncol2013; 49: 182–185.
28.
Bar-AdVZhangQEHarariPM, et al.Correlation between the severity of cetuximab-induced skin rash and clinical outcome for head and neck cancer patients: the RTOG experience. Int J Radiat Oncol Biol Phys2016; 95: 1346–1354.
29.
UozumiSEnokidaTSuzukiS, et al.Predictive value of cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Front Oncol2018; 8: 616.
30.
LacoutureMEAnadkatMBensadounRJ, et al.MASCC Skin toxicity study group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer2011; 19: 1079–1095.
31.
LacoutureMEMitchellEPPiperdiB, et al.Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol2010; 28: 1351–1357.
32.
YamamotoYUedaHYamamotoN, et al.The management of skin toxicity due to epidermal growth factor receptor inhibitors (EGFRIs) proposed by consensus conference held with volunteer dermatologists and oncologists. J Clin Therap Med2016; 32: 941–949.
33.
RittieLVaroniJKangS, et al.Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol2006; 126: 732–739.
34.
DeWittCASiroyAEStoneSP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol2007; 56: 500–505.
35.
HachisukaJDoiKMoroiY, et al.Successful treatment of epidermal growth factor receptor inhibitor-induced periungual inflammation with adapalene. Case Rep Dermatol2011; 3: 130–136.
36.
HongSHWongCWPrivalskyML. Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor. Mol Endocrinol1998; 12: 1161–1171.
37.
ScopeAAgeroALDuszaSW, et al.Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol2007; 25: 5390–5396.
38.
ChayaharaNMukoharaTTachiharaM, et al.Adapalene Gel 0.1% versus placebo as prophylaxis for anti-epidermal growth factor receptor-induced acne-like rash: a randomized left-right comparative evaluation (APPEARANCE). Oncologist2019; 24: 885–e413.
39.
PomerantzRGChirinosREFalo GeskinLJ, et al.Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Arch Dermatol2008; 144: 949–950.
40.
DeWittCASiroyAEStoneSP, et al.Acneiform eruptions associated with epidermal growth factor receptor targeted chemotherapy. J Am Acad Dermatol2007; 56: 500–505.
41.
GutzmerRWerfelTMaoR, et al.Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol2005; 153: 849–851.
42.
LehmannPZhengPLavkerRM, et al.Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J Invest Dermatol1983; 81: 169–176.
43.
EilersREJrGandhiMPatelJD, et al.Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst2010; 102: 47–53.
44.
BooneSLRademakerALiuD, et al.Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology2007; 72: 152–159.
